Rigel Pharmaceuticals Financial Ratios
NASDAQ: RIGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Rigel Pharmaceuticals ratio analysis
Rigel Pharmaceuticals earned a net margin of 124.7% in FY 2025, up from 9.8% a year earlier. Gross margin was 93.3% compared with a median of 98.5% over the prior 7 years. Return on equity reached 93.8%, meaning Rigel Pharmaceuticals generated 0.94 dollars of profit for every dollar of shareholders' equity, an unusually high figure that often reflects a small equity base after share buybacks.
Debt-to-equity stood at 0.13 versus 18.25 the year before, and the current ratio was 2.42. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Rigel Pharmaceuticals financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 2.15 | 17.56 | — | — | — | — | — | — | — | — |
| Price / sales | 2.56 | 1.70 | 2.16 | 2.13 | 30.27 | 54.38 | 57.88 | 85.12 | 1,093.08 | 110.21 |
| Price / book | 1.92 | 92.92 | — | — | 148.75 | 173.58 | 63.77 | 34.48 | 48.70 | 40.82 |
| Gross margin | 93.3% | 89.6% | 93.9% | 98.5% | 99.3% | 99.2% | 98.5% | 99.4% | — | — |
| Operating margin | 42.6% | 13.5% | -17.5% | -46.2% | -8.4% | -26.7% | -116.5% | -163.3% | -1,775.6% | -342.2% |
| Net margin | 124.7% | 9.8% | -21.5% | -48.7% | -12.0% | -27.4% | -112.8% | -158.3% | -1,739.3% | -339.6% |
| Free cash flow margin | 25.7% | 17.6% | -4.9% | -61.7% | 3.5% | -49.2% | -72.5% | -134.7% | -1,733.3% | -376.3% |
| Return on equity (ROE) | 93.8% | 531.8% | — | — | -59.0% | -87.4% | -124.3% | -64.1% | -77.5% | -125.8% |
| Return on assets (ROA) | 71.5% | 10.7% | -21.4% | -43.6% | -10.7% | -26.9% | -45.3% | -50.7% | -65.5% | -88.6% |
| Debt / equity | 0.13 | 18.25 | — | — | 0.66 | 0.59 | 0.19 | — | — | — |
| Current ratio | 2.42 | 2.13 | 1.86 | 1.78 | 2.43 | 2.18 | 2.04 | 4.94 | 6.40 | 3.37 |
| Revenue growth | 64.1% | 53.4% | -2.8% | -19.4% | 37.4% | 83.2% | 33.2% | 892.6% | -78.0% | — |
| EPS growth | 1,867.7% | — | — | — | — | — | — | — | — | — |